Anti-tumor immunity and mechanism of immunosuppression mediated by tumor cells: Role of tumor-derived soluble factors and cytokines

International Reviews of Immunology

Volumn 29, Issue 4, 2010, Pages 421-458

  Deepak, Praveen ^a   Acharya, Arbind ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Anti tumor immunity; Cytokines; Immunosuppression; Tumor bearing host; Tumor derived soluble factors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COLONY STIMULATING FACTOR 1; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; NITRIC OXIDE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN; CYTOKINE; TUMOR PROTEIN;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; HOST; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; SOLUBILITY;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSION; MICE; NEOPLASM PROTEINS; NEOPLASMS; SOLUBILITY;

EID: 77954811201     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.483027     Document Type: Review

References (258)

1. Burnet FM. Cancer-A biological approach. BMJ 1957; 1: 841-847.
2. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
3. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7: 3-25.
4. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55: 329-333.
5. Shankaran V, Ikeda H, Bruce AT, et al. IFN-γ and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 2001; 410: 1107-1111.
6. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
7. Dunn GP, Old LJ, Schreiber RD. The Three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-360.
8. Asghar SS. Membrane regulators of complement activation and their aberrant expression in disease. Lab Invest 1995; 72: 254-271.
9. Morgan BP, Rushmere NK, Harris CL. Therapeutic uses of recombinant complement receptors. Biochem Soc Trans 1998; 26: 49-54.
10. Matthews TJ, Collins JJ, Roloson GJ, et al. Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum. J Immunol 1981; 126: 2332-2336.
11. Ralph P, Nakoinz I. Differences in antibody dependent and nonspecific killing of tumor cells by macrophage cell lines. Cancer Res 1981; 41: 3546-3550.
12. Hibbs J Jr, Taintor R, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235:473-476.
13. Kubin M, Kamoun M, Trinchieri G. Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med 1994; 180: 211-222.
14. Becker Y. Dendritic cell activity against primary tumors: an overview. In Vivo 1993; 7: 187-191.
15. Nakano T, Oka K, Sugita T, Tsunemoto H. Anti-tumor activity of Langerhans cells in radiation therapy for cervical cancer and its modulation with SPG administration. In Vivo 1993; 7: 257-263.
16. + T-helper and a T-killer cell. Nature 1998; 393: 474-478.
17. Imahayashi S, Ichiyoshi Y, Yoshino I, et al. Tumor-infiltrating B cell-derived IgG recognizes tumor. Cancer Invest 2000; 18: 530-536.
18. Pfreundschuh M. Exploitation of the B cell repertoire for the identification of human tumor antigens. Cancer Chemother Pharmacol 2000; 46: S3-S7.
19. Cote RJ, Morrissey DM, Houghton AN, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci USA 1983; 80: 2026-2030.
20. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in anti-tumor immunity. Trends Immunol 2001; 22: 269-276.
21. MosmannTR, Sad S. The expanding universe of T cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
22. Fossati G, Taramelli D, Balsari A, et al. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int J Cancer 1984; 33: 591-597.
23. Slovin SF, Lackman RD, Ferrone S, et al. Cellular immune response to human sarcomas. I. Development, phenotype and specificity. J Immunol 1986; 137: 3042-3048.
24. Berke G. Functions and mechanisms of lysis induced by cytotoxic T lymphocytes and natural killer cells. In: Paul WE (Ed.): Fundamental Immunology (2nd Ed.). New York: Raven Press, pp. 735-764, 1989.
25. Rodolfo M, Salvi C, Bassi C, Parmiani G. Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-1 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model. Cancer Immunol Immunother 1990; 31: 28-36.
26. Young JD. Killing of target cells by lymphocytes: a mechanistic view. Physiol Rev 1989; 69: 250-314.
27. Herberman RB, Nunn ME, Holden HT, et al. Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer 1977; 19: 555-564.
28. Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71: 907-920.
29. Drake CG, Jaffee E, Pardoll DM. Mechanism of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
30. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
31. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1025.
32. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cell with PD-1 on tumor specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54: 307-314.
33. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296.
34. Manson LA. Does antibody-dependent epitope masking permit progressive tumor growth in the face of cell-mediated cytotoxicity. Immunol Today 1991; 12: 352-355.
35. 35] KE Hellstrom, Hellstrom I. Principles of tumor immunity, tumor antigens. In: VT DeVita Jr, Hellman S, Rosenberg SA (Eds.). Biological Therapy of Cancer. Philadelphia: Lippincott, p. 42, 1991.
36. 36] Baldwin RW, Robbins RA. Humoral factor abrogating cell-mediated immunity in the tumor-bearing host. Curr Topic Microbiol Immunol 1975; 72: 21-53.
37. 37] Hellstrom KE, Hellstrom I. Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 1974; 18: 209-277.
38. 38] Haskill JS, Key M, Radov LA, et al. The importance of antibody and macrophage in spontaneous and drug-induced regression of T1699 mammary adenocarcinoma. J Reticuloendo Soc 1979; 26: 417-425.
39. 40] Wood GW, Morantz RA, Tilzer SA, Gollahon KA. Immunoglobulin bound in vivo to Fc receptor positive cells in humans central nervous system tumor. J Natl Cancer Inst 1980; 64: 411-418.
40. 41] Wood GW, Tilzer SA, Gollahon KA, Lindsay JM. Association between immunoglob- ulin and IgG Fc receptors in primary methylcholanthrene induced sarcoma. Can- cerRes 1979; 39: 4588-4593.
41. 42] Whitford P, Mallon EA, George WD, Campbell AM. Flow cytometric analysis of tumor infiltrating lymphocytes in breast cancer. Br J Cancer 1990; 62: 971-975.
42. 43] Szuro-Sudol A, Murray HW, Nathan CF. Suppression of macrophage antimicrobial activity by a tumor cell product. J Immunol 1983; 131: 384-387.
43. 44] Hasday JD, Shah EM, Lieberman AP. Macrophage TNF release is induced by contact with some tumors. J Immunol 1990; 145: 371-379.
44. 45] Janicke R, Mannel DN. Distinct tumor cell membrane constitutes activate human monocyte for TNF synthesis. J Immunol 1990; 144: 1144-1150.
45. 46] Sotomayor EM, Fu YX, Lopez-Cepero M, et al. Role of tumor-derived cytokines on the immune system of mice bearing adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J Immunol 1991; 147: 2816-2823.
46. Hannigan BM, McNally OR, Kirrane O, Eason SJ. Tumor cell inhibition of macrophage cytokine activity. FEMS Microbiol Immunol 1992; 105: 283-288.
47. .Zembala M, Siedlar M, Marcinkiewicz J, Pryjma J. Human monocytes are stimulated for nitric oxide release in vitro by some tumor cells but not by cytokine and polysaccharide. Eur J Immunol 1994; 24: 435-439.
48. Shrivastava A, Sodhi A, Kumar R. Activation of murine macrophages by tumor cells. Int J Immunopathol Pharmacol 1995; 8: 45-56.
49. Peters C, Lotzerich H, Niemeir B, et al. Exercise, cancer and immune response of monocytes. Anticancer Res 1995; 15: 175-179.
50. Kumagai H, Masuda T, Sakashita M, et al. Modulation of macrophage activity in tumor-bearing mice by cytogenin. J Antibiotics 1995; 48: 321-325.
51. Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: potential targets of anti-cancer therapy. Euro J Cancer 2004; 42: 717-727.
52. Kumar S, Deepak P, Acharya A. Hsp70 modulates the enhanced production of reactive intermediate metabolites and a pro-inflammatory cytokine TNF-α expression in a T-cell lymphoma. Eur J Inflam 2006; 4: 157-169.
53. Kumar S, Deepak P, Acharya A. Hsp70 induces Th1 polarization through tumor- associated macrophages in a T-cell lymphoma. Neoplasma 2007; 54: 113-122.
54. North SM, Nicolson GL. Heterogeneity in the sensitivity of the 13762N rat mammary adenocarcinoma cell clones to cytolysia mediated by extra- and intra-tumoral macrophages. Cancer Res 1985; 45: 1453-1458.
55. McBridge WH. Phenotype and functions of intra-tumoral macrophages. Biochim- ica et Biophysica Acta 1986; 865: 27-41.
56. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumor- associated macrophages. Immunol Today 1992; 13: 265-270.
57. Andreesen R. Macrophage-directed tumor immunotherapy revisited past and future of an old doctor's dilemma. Immunol Res 1993; 144: 291-294.
58. Evans R, Alexander P. Mechanism of immunologically specific killing of tumor cells by macrophages. Nature 1972; 236: 168-170.
59. Chapes SK, Gooding LR. Evidence for the involvement of cytotoxic macrophages in rejection of SV-40-induced tumors. J Immunol 1985; 135: 21922198.
60. Yamazaki M, Okutomai T. Augmentation of release of cytotoxin from murine bone marrow and peritoneal macrophages by tumor transplantation. Cancer Res 1989; 49: 352-356.
61. Garraud O, Faucher A, Legrand E. Impairment of monocyte functions in advanced head and neck cancer. Immunol Lett 1988; 18: 213-318.
62. Kan-Mitchell J, Hengst JC, Kempf RA, et al. Cytotoxic activity of human pulmonary alveolar macrophages. Cancer Res 1985; 45: 453-458.
63. Kerrebijn JD, Balm AJ, Knegt PP, et al. Macrophages and dendritic cells infiltration in head and neck squamous cell carcinoma: An immunohistochemical study. Cancer Immunol Immunother 1994; 38: 31-37.
64. Skew D, Burger CJ, Elgert KD. Tumor growth and adherence change the expression of macrophage Mac-2. Cancer Lett 1993; 69: 67-74.
65. Walker TM, Burger CJ, Elgert KD. Tumor growth alters macrophage responsiveness to M-CSF during reactivity against allogeneic and syngeneic MHC class II molecules. Immunol Invest 1993; 22: 463-476.
66. Cameron DJ, Stromberg BV. The ability of head and neck cancer patients to kill tumor cells. Effect of prostaglandin inhibitors in cytotoxicity. Cancer 1984; 54: 2403-2408.
67. Allen C, Hogg N. Elevation of infiltrating mononuclear phagocytes in human col- orectal tumors. J Natl Cancer Inst 1987; 78: 465-470.
68. Kuda T, Yasumoto K, Yano T, et al. Role of anti-tumor activity of alveolar macrophages in lung cancer patients. Cancer Res 1987; 47: 2199-2202.
69. Jhaver K, De A, Advani S, Nadkarni J. Production of IL-1 and TNF in non-Hodgkin's lymphoma patients. Cancer Immunol Immunother 1991; 34: 123-127.
70. Evans R, Haskill S. In: Herberman RB, Friedman H (Eds.). The Reticuloendothelial System. A Comprehensive Treatise (Cancer Vol. 5). New York: Plenum Press, pp. 155-176, 1983.
71. Almand B, Resser J, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-1766.
72. Almand B, Clark J, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients as a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
73. Bronte V, Apolloni E, Cabrelle A, et al. Identification of a CD11b(+)/Gr- 1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 2000; 96: 3838-3846.
74. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002; 6: 293-1198
75. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164: 2214-2220.
76. Bloom ET, Babbit JT. Monocyte-mediated augmentation of human natural cell- mediated cytotoxicity. Cell Immunol 1985; 91: 21-32.
77. DeBoer KP, Braun DP, Harris JE. Natural cytotoxicity and antibody-dependent cytotoxicity in solid tumor cancer patients: Regulation by the adherent cells. Clin Immunol Immunopathol 1982; 23: 133-144.
78. Schulof RS, Michitsch RW, Livingston PO, Gupta S. Monocyte-mediated suppression of lymphocyte cytotoxic activity for cultured autologous melanoma cells. Cell Immunol 1981; 57: 529-532.
79. Roth MD, Golub SH. Inhibition of LAK cell function by alveolar macrophages. Cancer Res 1989; 49: 4690-4695.
80. Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD-40-ligand. J Exp Med 1997; 185: 1101-1111.
81. Kim R, Emi M, Tanabe K, Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007; 121: 149-157.
82. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type-1 interferon and interleukin-6. Immunity 2003; 19: 225-234.
83. Poeck H, Wagner M, Battiany J, et al. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T cell help. Blood 2004; 103: 3058-3064.
84. Tabera S, Perez-Simon JA, Diez-Campelo M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B lymphocytes. Haemato- logica 2008; 93: 1301-1309.
85. Rissoan M, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-1186.
86. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-γ- secreting melanoma specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003; 33: 1052-1062.
87. Hartmann E, Wollenberg B, Rothenfusser S, et al. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 2003; 63: 6478-6487.
88. + regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65: 5020-5026.
89. Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasma- cytoid dendritic cells with multiple myeloma cells: A therapeutic target. Cancer Cell 2009; 16: 309-323.
90. Fu Y, Paul RD, Wang Y, Lopez DM. Thymic involution and thymocyte phenotypic alteration induced by murine mammary adenocarcinomas. J Immunol 1989; 143: 4300-4307.
91. Lopez DM, Paul RD. Analysis of lymphoid cells responding to virus and tumor- associated antigens in spleens of syngenic mouse mammary tumor systems with low and high oncogenic potentials. J Natl Cancer Inst 1982; 69: 1403-1409
92. Zou JP, Shimizu J, Ikegame K, et al. Tumor-immunotherapy with the use of tumor antigen-pulsed antigen presenting cells. Cancer Immunol Immunother 1992; 35: 1-6.
93. Gregorian SK, Battisto JR. Immunosuppression in murine renal cell carcinoma. I. Characterization of extent, severity and sources. Cancer Immunol Immunother 1990; 31: 325-334.
94. Tada T, Sano H, Sato S, et al. Immune dysfunction expressed selectively on L3T4+ T cells in the tumor-bearing state. J Leukoc Biol 1990;47: 149-157.
95. Tada T, Ohzeki S, Utsumi K, et al. Transforming growth factors-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in the tumor-bearing state. J Immunol 1991; 146: 1077-1082.
96. Li XF, Takiuchi H, Zou JP, et al. Transforming growth factors-mediated immunosuppression in tumor-bearing state: Enhanced production of TGF-β and a progressive increase in TGF-β susceptibility of anti-CD4+ cell function. Jpn J Cancer Res 1993; 84: 315-325.
97. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995; 155: 3124-3134.
98. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alteration in signal transduction molecule in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-1798.
99. Travis J. Do tumor-altered T cells depress immune responses? Science 1992; 258: 1732-1733.
100. Goedegebuure PS, Eberlin TJ. The role of CD4+ tumor infiltrating lymphocytes in human solid tumors. Immunol Res 1995; 14: 119-131.
101. Kurt RA, Park JA, Panelli MC, et al. T lymphocytes infiltrating sites of tumor rejection and progression, display identical V usage for different cytotoxic activities. J Immunol 1995;154: 3969-3974.
102. Mukherjee BN, Chakraborty G, Sivanandan M. T cell clones that reacts against autologous human tumor. Immunol Rev 1990; 116: 33-62.
103. Yoshino I, Yano T, Murata T, et al. Tumor reactive T cells accumulate in lung cancer tissue but fail to respond due to tumor-derived factors. Cancer Res 1992; 52: 775-781.
104. Whiteside TL, Jost LM, Herberman RB. Tumor infiltrating lymphocytes: Potential and limitations of their use for cancer therapy. Crit Rev Oncol Hematol 1992; 12: 25-47.
105. Marx J. The T cell receptor begins to reveal its many facets. Science 1995; 267: 459-460.
106. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
107. + regulatory T cell population by non-Hodgkin's lymphoma. Blood 2008; 111: 5359-5370.
108. Baumgartner J, Wilson C, Palmer B, et al. Melanoma induces immunosup- pression by up-regulating FoxP3(+) regulatory T cells. J Surg Res 2007; 141: 72-77.
109. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20: 241-246.
110. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor specific tolerance. J Immunol 2007; 178: 2155-2162.
111. Grossman W, Verbsky J, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589-601.
112. Castriconi R, Cantoni C, Chiesa MD, et al. Transforming growth factor β 1 inhibits expression of NK p30 and NKG2D receptor. Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 2003; 100: 4120-4125.
113. Fantini MC, Becker C, Monteleone G, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down- regulation of Smad7. J Immunol 2004; 172: 5149-5153.
114. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
115. Uhlig HH, Coombes J, Mottet C, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 2006; 177: 5852-5860.
116. Kamanaka M, Kim ST, Wan YY, et al. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knock in tiger mouse. Immunity 2006; 25: 941-952.
117. Tato CM, JJ O'Shea. Immunology: What does it mean to be just 17? Nature 2006; 441: 166-168.
118. Fossiez F, Banchereau J, Murray R, et al. Interleukin-17. Int Rev Immunol 1998; 16: 541-551.
119. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-189.
120. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-β induces development of the T(H)17 lineage. Nature 2006; 441: 231-234.
121. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238.
122. Miyahara Y, Odunsi K, Chen W, et al. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Nat Ass Sci USA 2008; 105: 15505-15510.
123. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
124. Zhu J, Davidson TS, Wei G, et al. Down-regulation of Gfi-1 expression by TGF-β is important for differentiation of Th17 and CD103+ inducible regulatory T cells. J Exp Med 2009; 206: 329-341.
125. Stutman O, Figarella EF, Paige CJ. Natural cytotoxic (NC) cells against solid tumors in mice: General characteristics and comparison to natural killer (NK) cells. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 187, 1980.
126. Ehrlich R, Efrate M, With IP. Cytotoxicity and cytostasis mediated by splenocytes of mice subjected to chemical carcinogens and of mice bearing primary tumors. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 1073, 1980.
127. Gerson JM. Systemic and in situ natural killer activity in tumor-bearing mice and patients with cancer. In: Herberman RB (Ed.): Natural Cell-Mediated Immunity against Tumors. New York: Academic Press, p. 1047, 1980.
128. Lala PK, Santer V, Libenson H, Parhar RS. Changes in host NK cell population in mice during tumor development. I. Kinetics and in vivo significance. Cell Immunol 1985; 93: 250-264.
129. Moy PM, Holmes EC, Golub SH. Depression of NK cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 1985; 45:
130. Kurosawa S, Matsuzaki G, Harada M, et al. Early appearance and activation of NK cells in human tumor-infiltrating lymphoid cells during tumor development. Eur J Immunol 1993; 23: 1029-1033.
131. Budzynski W, Chirigas M, Gruys E. Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2. Cancer Immunol Immunother 1987; 24: 253-258.
132. Parhar RS, Lala PK. Changes in host NK cell population in mice during tumor development. II. Mechansim of suppression of NK activity. Cell Immunol 1985; 93: 265-279.
133. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995; 41: 111-121.
134. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 2004;172:989-999.
135. Murgita RA, Tormasi TB. Suppression of the immune response by alpha-feto- protein. J Exp Med 1975; 141: 269-286.
136. Oh SK, Moolton FL. Nonspecific immunosuppressive factors in malignant ascites: Further characterization and possible relationship to erythrocyte receptors of human peripheral T cells. J Immunol 1981; 127: 2300-2307.
137. Nelson M, Nelson DS. Macrophages and resistance to tumors. I. Inhibition of delayed-type hypersensitivity reactions by tumor cells and by soluble products affecting macrophages. Immunology 1978; 34: 277-290.
138. Fulton AM, Heppner GH. Relationship of prostaglansin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinoma. Cancer Res 1985; 45: 4779-4784.
139. Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production: role of tumor-derived IL-10, TGF- fi, and prostaglandin E2. J Immunol 1994; 153: 1674-1686.
140. Myers MJ, Hanafin WP, Schook LB. Augmented PGE2 production following exposure to dimethylnitrosamine in vitro: Relevance to suppressed T cell responses. Immunophrmacol 1989; 18;115-124.
141. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006; 25: 323-331.
142. Harizi H, Juzan M, Pitard V, et al. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002; 68: 2255-2263.
143. Sombroek CC, Stam AGM, Masterson AJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168: 4333.
144. Gemsa D, Leser HG, Deimann W, Resch K. Suppression of T cell proliferation during lymphoma growth in mice: Role of PGE2-producing suppressor macrophages. Immunobiology 1982; 161: 385-391.
145. Hakamori S. Structure, organization, and function of glycosphigolipids in membrane. Curr Opin Hematol 2003; 10: 16-24.
146. Hakamori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50: 733-764.
147. Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregula- tory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983; 43: 3808-3813.
148. Bharti AC, Singh SM. Induction of apoptosis in bone marrow cells by gangliosides produced by a T cell lymphoma. Immunol Lett 2000; 72: 39-48.
149. Bharti AC, Singh SM. Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int Immunopharmacol 2001; 1: 155-165.
150. Birkle S, Zeng G, Gao L, et al. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85: 455-463.
151. Shurin GV, Shurin MR, Bykovskaia S, et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation function. Cancer Res 2001; 61: 363-369.
152. Peguet-Navarro J, Sportouch M, Popa I, et al. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apop- tosis. J Immunol 2003; 170: 3488-3494.
153. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
154. Ohm JE, Shurin MR, Esche C, et al. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999; 163: 3260-3368
155. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-4166.
156. Bronte V, Chappell DB, Apolloni E, et al. Unopposed production of granulocyte- macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 5728-5737.
157. Fu Y, Watson G, Jimenez JJ, et al. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990; 50: 227-234.
158. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 1999; 21: 241-252.
159. Serafini P, Carbley R, Noonan KA, et al. High dose GM-CSF-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-6343.
160. Young M, Wright M, Young M. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol Immunother 1991; 33: 146-152.
161. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-3192.
162. Fixe P, Praloran V. Macrophage colony-stimulating-factor (M-CSF or CSF-1) and its receptor: Structure-function relationships. Eur Cytokine Netw 1997; 8: 125-136.
163. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: Complexity in action. Trends Cell Biol 2004; 14: 628-638.
164. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 2006; 18: 39-48.
165. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony stimulating factor. Blood 1998; 92: 4778-4791.
166. Ding A, Nathan CF, Graycar J, et al. Macrophage deactivating factor and transforming growth factor 1, 2, and 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J Immunol 1990; 145: 940-944.
167. Sulitzeanu D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247-267.
168. Lindeskog M, Medstrand P, Blomberg J. Sequence variation of human endogenous retrovirus ERV-9 related elements in an env region corresponding to an immunosuppressive peptide: Transcription in neoplastic cells. J Virol 1993; 67: 1122-1126.
169. Lindvall M, Sjogren HO. Inhibition of rat yolk sac tumor growth in vivo by a monoclonal antibody to the retroviral molecule P15E. Cancer Immunol Immunother 1991; 33: 21-27.
170. Amar M, Amit N, Babin-Chevaye C, et al. Effect of a factor released by K562 malignant cells in culture on human neutrophil bactericidal activity. Infect Immun 1991; 59: 2673-2676.
171. Hoffman RA, Langrehr JM, Billiar TR, et al. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990; 145: 2220-2226.
172. Mills CD. Molecular basis of "suppressor" macrophages. Arginine metabolism via NO synthase pathway. J Immunol 1991; 146: 2719-2723.
173. Webb DS, Shimizu Y, van Seventer GA, et al. LFA-3, CD44 and CD45: Physiologic trigger of human monocyte TNF and IL-1 release. Science 1990; 249: 1295-1297.
174. Metzger Z, Hoffeld JT, Oppenheim JJ. Macrophage mediated suppression: Evidence for participation of both hydrogen peroxide and prostaglandin in suppression of murine lymphocytes proliferation. J Immunol 1980; 124: 983-988.
175. Storz P. Reactive oxygen species in tumor progression. Front Biosci 2005; 10: 1881-1896.
176. Hofmann T, Schmitt B, Mack B, et al. New target genes for tumor-derived soluble factors in primary monocytes. Cancer Genom Proteom 2004; 1: 167-176.
177. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. J Immunol Rev 2004; 22: 275-293.
178. Ben-Baruch A. Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 2006; 16: 38-52.
179. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: Present and future therapeutic targets. Nat Immunol 2005; 6: 1182-1190.
180. Luo J-L, Maeda S, Hsu L-C, et al. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297-305.
181. Yang H, Bocchetta M, Kroczynska B, et al. TNF-α inhibits asbestos-induced cy- totoxicity by a NF-κB-dependent pathway, a possible mechanism for asbestos- induced tumorigenesis. Proc Natl Acad Sci USA 2006; 103: 345-505.
182. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003; 3: 276-285.
183. MocellinS, Rossi CR, PilatiP, NittiD. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16: 35-53.
184. Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol 1998; 64: 275-290.
185. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-831.
186. Arnott CH, Scott KA, Moore RJ, et al. Expression of both TNF-α receptor subtypes is essential for optimal skin tumor development. Oncogenes 2004; 23: 1902-1910.
187. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.
188. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor- related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161-169.
189. Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202: 139-156.
190. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
191. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleuikin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155-174.
192. Witowski J, Ksiazek K, Jorres A. Interleukin-17: A mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567-579.
193. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
194. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin-17. Nat Immunol 2005; 6: 1133-1141.
195. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin- 17 and tumor necrosis factor-α is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004; 279: 2559-2567.
196. Tartour E, Fossiez F, Joyeux I, et al. Interleukin-17, a T cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999; 59: 3698-3704.
197. Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angio- genic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2 dependent angiogenesis. J Immunol 2005; 175: 6177-6189.
198. Numasaki M, Fukushi J-I, Narula SK, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101: 2620-2627.
199. Hao JS, Shan BE. Immune enhancement and anti-tumor activity IL-23. Cancer Immunol Immunother 2006; 55: 1426-1431.
200. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-KB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006; 176: 5652-5661.
201. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumor incidence and growth. Nature 2006; 442: 461-465.
202. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-738.
203. Santra S, Ghosh SK. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines during in vivo progression of a murine B lymphoma. Cancer Immunol Immunother 1997; 44: 291-300.
204. Conticello C, Pedini F, Zeuner A, et al. IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic poteins. J Immunol 2004; 172: 5467-5477.
205. Li Z, Jiang J, Wang Z, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res 2008; 68: 8668-8687.
206. Takeuchi T, Ueki T, Sasaki Y, et al. Th2-like response and anti-tumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 1997; 43: 375-781.
207. Fallon PG, Jolin HE, Smith P, et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity 2002; 17: 7-17.
208. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002; 13: 357-368.
209. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-2512.
210. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-324.
211. Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signalling and survival pathways. Hum Immunol 1999; 60: 921-927.
212. Bommert K, Bargou RC, Stuhmer T. Signaling and survival pathways in multiple myeloma. Eur J Cancer 2006; 42: 1574-1580.
213. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21: 491-501.
214. Cozen W, Gill PS, Ingles SA, et al. IL-6 levels and genotypes are associated with risk of young adult Hodgkin lymphoma. Blood 2004; 103: 3216-3221.
215. + T-regulatory cells and systemic collapse of anti-tumor immunity. Immunology 2001; 103: 449-457.
216. Moore KW, Waal Malefyt R de, Coffman RL, A O'Garra. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001; 19: 683-765.
217. Yang AS, Lattime EC. Tumor-induced IL-10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003; 63: 2150-2157.
218. Steinbrink K, M Wolfl, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159: 4772-4780.
219. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-369.
220. Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. J Leukoc Biol 2001; 69: 129-137.
221. McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 1993; 150: 5436-5444.
222. McKenzie AN, Culpepper JA, Waal Malefyt R de, et al. IL-13, a T cell derived cytokine that regulates human monocyte and B cell function. Proc Natl Acad Sci USA 1993; 90: 3735-3739.
223. Minty A, Chalon P, Derocq JM, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362: 248-250.
224. Waal Malefyt R de, Figdor CG, Huijbens R, et al. Effects of IL-13 on phenotype, cytokine production and cytotoxic function of human monocytes: Comparison with IL-4 and modulation by IFN-γ or IL-10. J Immunol 1993; 151: 6370-6381.
225. VerceUi D, Jabara HH, Lee DW, et al. Human recombinant interleukin 4 induces FceR2/CD23 on normal human monocytes. J Exp Med 1988; 167: 1406-1416.
226. Te Velde AA, Klomp JPG, Yard BA, et al. Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4. J Immunol 1988; 140: 1548-1554.
227. Littman BH, Dastvan FF, Carlson PL, Sanders KM. Regulation of monocyte/macrophage C2 production and HLA-DR expression by IL-4 (BSF-1) and IFN-γ. J Immunol 1989; 142: 520-525.
228. Te Velde AA, Rousset E, Peronne C, et al. IFN-γ and IFN-γ have different regulatory effects on IL-4 induced membrane expression of FcεRIIb and release of soluble FcεRIIb by human monocytes. J Immunol 1990; 144: 3052-3059.
229. Becket S, Daniel EG. Antagonistic and additive effects of IL-4 and IFN-γ on human monocytes and macrophages: Effects on Fc receptors, HLA-D antigens, and superoxide production. Cell Immunol 1990; 129: 351-362.
230. Gerrard TL, Dyer DR, Mostowski HS. IL-4 and granulocyte-macrophage colony stimulating factor selectively increase HLA-DR and HLA-DP antigens, but not HLADQ antigens on human monocytes. J Immunol 1990; 144: 4670-4674.
231. Bogdan C, Nathan C. Modulation of macrophage functions by transforming growth factor β, interleukin-4, and interleukin-10. Ann NY Acad Sci 1993; 685: 713-739. (Pubitemid 23238554)
232. Hart PH, Vitti GF, Burgess DR, et al. Potential anti-inflammatory effects of inter- leukin 4: Suppression of human monocyte tumor necrosis factor ct, interleukin 1 and prostaglandin E2. Proc Natl Acad Sci USA 1989; 86: 3803-13087
233. Essner R, Rhoades K, McBride WH, et al. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857-3861.
234. Donnelly RP, Fenton MJ, Kaufman JD, Gerrard TL. IL-1 expression in human monocytes is transcriptionally and post-transcriptionally regulated by IL-4. J Immunol 1991; 146: 3431-3436.
235. Hamilton JA, Whitty GA, Royston AKM, et al. Interleukin 4 suppresses gran- ulocyte colony-stimulating factor and granulocyte-macrophage colony stimulating factor levels in stimulated human monocytes. Immunology 1992; 76: 566-571.
236. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4- independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730-3734.
237. BG Cocks, Waal Malefyt R de, Galizzi J-P, et al. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int Immunol 1993; 5: 657-663.
238. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med 1994; 179: 135-143.
239. Punnonen J, Vries JE de. IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. J Immunol 1994; 152: 1094-1102.
240. Tangye SG, Ferguson A, Avery DT, et al. Isotype switching by human B cells is division-associated and regulated by cytokines. J Immunol 2002; 169: 4298-4306.
241. Lai YH, Mosmann TR. Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production. J Immunol 1999; 162: 78-87.
242. Bost KL, Holton RH, Cain TK, Clements JD. In vivo treatment with anti- interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice. Immunology 1996; 87: 633-641.
243. Ford D, Sheehan C, Girasole C, et al. The human B cell response to IL-13 is dependent on cellular phenotype as well as mode of activation. J Immunol 1999; 163: 3185-3193.
244. Kuroki A, Iyoda M, Shibata T, Sugisaki T. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int 2005; 68: 302-310.
245. Zurawski G, Vries JE de. Interleukin-13, an interleukin-4 like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15: 19-26.
246. Vries JE de. The role of IL-I 3 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102: 165-169.
247. Gauchat JF, Schlagenhauf E, Feng NP, et al. A nobel 4-kd interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells including an alternate type II interleukin-4/Interleukin-13 receptor. Eur J Immunol 1997; 27: 971-978.
248. Curiel RE, Lahesmaa R, Subleski J, et al. Identification of a Stat-6-responsive element in the promoter of the human interleukin-4 gene. Eur J lmmunol 1997; 27: 1982-1987.
249. Jinquan T, Deleuran B, Gesser H, et al. Regulation of human T lymphocyte chemo- taxis in vitro by T cell-derived cytokines IL-2, IFN-y, IL-4, IL-10 and IL-13. J Immunol 1995; 154: 3742-3752.
250. Terabe M, Matsui S, Noben-Trauth N, et al. NKT cell-mediated repression of tumor-immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-520.
251. Terabe M, Park JM, Berzofsky JA. Role of IL-13 in regulation of antitumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79-85.
252. Chen WJ, Wahl SM. TGF-β: The missing link in CD4+CD25+ regulatory T cell- mediated immunosuppression. Cytokine Growth Factor Rev 2003; 14: 85-89.
253. Becker C, Fantini MC, Neurath MF. TGF-β as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 2006; 17: 97-106.
254. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-β-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202: 919-929.
255. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J 1999; 18: 1280-1291.
256. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129.
257. Chen M-L, Pittet MJ, Gorelik L, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-424.
258. Ghiringhelli F, Ménard C, Terme M, et al. CD4+CD25+regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005; 202: 1075-1085.